Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11)
Introduction: The BENEFIT trial demonstrated improved clinical outcomes in patients with a clinically-isolated syndrome (CIS) and early treatment with interferon beta-1b up to 11 years after randomization. Cognitive outcomes and cognitive fatigue data at Year 11 are presented here.
Conclusion: Superior PASAT performance in the early treatment group occurred early and persisted over 11 years. SDMT results are comparable to data from other MS populations of similar disease duration and healthy volunteers. These findings add more objective evidence that confirms the beneficial impact of early treatment with interferon beta-1b on the clinical course of MS.